fda compounding glp-1 enforcement news Crackdown FDA GLP-1 Compounding Crackdown |
Description
Optum Rx is launching a new weight management program aimed at improving outcomes and addressing affordability
As global demand rises for effective metabolic therapies, GLP-1 drug development remains one of the fastest-growing segments in biopharma innovation
The misuse of GLP-1 drugs without clinical oversight can lead to severe health complications
Fast delivery across the UK.
Take the free 2-minute quiz today.
At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems
